Fixed drug eruption secondary to etoricoxib.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Churchill Livingstone Country of Publication: Scotland NLM ID: 8405235 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1940 (Electronic) Linking ISSN: 02664356 NLM ISO Abbreviation: Br J Oral Maxillofac Surg Subsets: MEDLINE
    • Publication Information:
      Original Publication: Edinburgh, U.K. : Churchill Livingstone, c1984-
    • Subject Terms:
      Etoricoxib*/adverse effects ; Drug Eruptions*/etiology ; Pyridines*/adverse effects ; Cyclooxygenase 2 Inhibitors*/adverse effects ; Sulfones*/adverse effects; Humans ; Female ; Male ; Middle Aged ; Mouth Mucosa/pathology ; Mouth Mucosa/drug effects ; Hypersensitivity, Delayed/chemically induced
    • Abstract:
      Fixed drug eruptions (FDE) are adverse cutaneous drug reactions and a form of delayed type 4 hypersensitivity reaction characterised by recurrent lesions at the same site each time a specific drug is taken. They most commonly result in cutaneous lesions presenting as an erythematous round or oval macule or plaque. FDEs have rarely been reported to affect oral mucous membranes and tend to have a bullous or aphthous-like appearance with erythema. Almost half of patients report an increase in the severity of symptoms with prolonged exposure to the offending medication. The most commonly attributed classes of drug are antibiotics (tetracyclines and sulphonamides) alongside non-steroidal anti-inflammatory drugs. Cutaneous adverse reactions to etoricoxib, a highly selective COX-2 inhibitor, have been reported. Here we describe an adverse reaction restricted to the oral mucosa.
      (Copyright © 2024 The British Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.)
    • Contributed Indexing:
      Keywords: FDE; Fixed drug eruption; Oral ulceration
    • Accession Number:
      WRX4NFY03R (Etoricoxib)
      0 (Pyridines)
      0 (Cyclooxygenase 2 Inhibitors)
      0 (Sulfones)
    • Publication Date:
      Date Created: 20240530 Date Completed: 20240708 Latest Revision: 20240911
    • Publication Date:
      20240912
    • Accession Number:
      10.1016/j.bjoms.2024.05.001
    • Accession Number:
      38816329